title: [Efficacy and tolerability of 5% minoxidil solution (Carexidil®) in male and female androgenetic alopecia: a 6-month open multicentric study].
abstract: OBJECTIVE
  The aim of the study was to evaluate efficacy and safety of 5% Carexidil solution®, applied twice a day on the scalp, on male and female androgenetic alopecia.
  
  
  METHODS
  The 6 month-study was performed in three Italian dermatological centers. Evaluation of efficacy was performed with subjective and objective methods, including operator and patient assessments, global photography and videodermoscopy.
  
  
  RESULTS
  Global photography revealed that after 6 months of treatment with 5% Carexidil solution®, androgenetic alopecia was improved in all 32 females and 16 males. Alopecia stopped to progress in 6 males. Scalp videodermoscopy confirmed the results. Some patients complained of increased hair greasiness, others complained of mild scalp itching. Two female patients developed contact sensitization to minoxidil, confirmed by patch test, 2 a mild malar-temporal hypertrichosis. All patients were satisfied by treatment and continued it after the end of the study.
  
  
  CONCLUSIONS
  Our study confirms the data of the literature and the evidence coming from years of clinical experience, that twice a day topical application of 5% minoxidil solution, Carexidil ®, is effective in the treatment of male and female androgenetic alopecia, with evident efficacy already after 6 months.
authors.affiliation: Department of Internal Medicine, University of Bologna, Bologna, Italy. biancamaria.piraccini@unibo.it
authors.forename: B
authors.initials: B
authors.lastname: Piraccini
authors.forename: M
authors.initials: M
authors.lastname: Starace
authors.forename: A
authors.initials: A
authors.lastname: Alessandrini
authors.forename: M
authors.initials: M
authors.lastname: Guarrera
authors.forename: M C
authors.initials: MC
authors.lastname: Fiorucci
authors.forename: S
authors.initials: S
authors.lastname: Lorenzi
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000188:drug therapy* / Q000473:pathology; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D046169:Dermoscopy; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D008914:Minoxidil / Q000008:administration & dosage* / Q000009:adverse effects; D017060:Patient Satisfaction; D011788:Quality of Life; D012720:Severity of Illness Index; D012996:Solutions; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects; D014743:Videotape Recording
chemical_list: D003879:Dermatologic Agents; D012996:Solutions; D014665:Vasodilator Agents; D008914:Minoxidil